Kynurenine aminotransferase and products thereof for the treatment of inflammatory bowel diseases
AssigneesInstitut National de Recherche Pour L'Agriculture, L'Alimentation et L’Environnement, Institut National Des Sciences Et Industries Du Vivant Et De L'environnement, Sorbonne Universite, Assistance Publique-Hopitaux de Paris, Inserm (Institut National De La Sante Et De La Recherche Medicale), Universite Paris-Saclay
InventorsHARRY SOKOL, CHLOÉ MICHAUDEL, PHILIPPE LANGELLA, ANNE AUCOUTURIER, LUIS BERMUDEZ
Life of this patent
Estimating the term…
Abstract
The present invention relates to the treatment of inflammatory bowel diseases with a kynurenine aminotransferase, a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or any pharmaceutically acceptable salt or solvate thereof.
Claims18
1-19. (canceled)
A method for treating an inflammatory bowel disease in a subject, said method comprising administering to the subject a composition comprising:
- a kynurenine aminotransferase (KAT), and/or
- a living recombinant bacterium which has been genetically modified to express and secrete said kynurenine aminotransferase, and/or
- a product of said kynurenine aminotransferase which is xanthurenic acid, a derivative thereof, or a pharmaceutically acceptable salt or solvate thereof.
Dependencies are inferred from the claim text.